Sana Biotechnology Inc vs Warner Music Group Corp — how do they compare? Sana Biotechnology Inc trades at $2.79 (market cap $836.71M), while Warner Music Group Corp trades at $28.72 (market cap $15.12B). The key difference: Warner Music Group Corp is far larger — about 18.1× Sana Biotechnology Inc's market cap, and Warner Music Group Corp pays a 2.77% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Warner Music Group Corp for 96 Days on average.
| SANA | WMG | |
|---|---|---|
Market Cap | $836.71M | $15.12B |
Volume | 4,507,444 | 2,966,414 |
Sector | Health | Media |
52-Week High | $5.92 | $34.72 |
52-Week Low | $2.68 | $23.65 |
Typical Hold Time | 23 Days | 96 Days |
Enterprise Value | $749.96M | $19.42B |
Dividend Yield | — | 2.77% |
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Warner Music Group (WMG) trades at $28.91, up 2.66% on the day, with a bullish technical outlook and strong analyst support. Recent earnings have beaten expectations, with Q2 2026 EPS of $0.38 exceeding the $0.3435 forecast. The company's revenue growth is solid, projected to reach $7.3B in 2026, and it maintains a high return on equity of 92.72%. Positive news includes strategic AI partnerships and a renewed licensing deal with NetEase Cloud Music.
The stock presents a compelling opportunity with a consensus price target of $39.50, implying significant upside. However, risks include recent net cash outflows, a high P/E ratio of 23.12, and competitive pressures in the evolving music industry. Investor sentiment is buoyed by institutional buying and AI-driven growth prospects, but execution on cost management and streaming market share remains critical.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →